Wichita Urology Group | Wichita, KS
Status and phase
Conditions
Treatments
About
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.
Full description
Participants will be randomized 1:1 to cretostimogene grenadenorepvec after TURBT (Arm A) vs observation after TURBT (Arm B).
Participants in Arm A will receive an induction course and then quarterly maintenance courses of cretostimogene through Month 13, if there is no disease recurrence.
Disease status will be assessed using urine cytology, complete bladder visualization (e.g., cystoscopy), and directed TURBT/biopsy (if indicated) every 3 months for the first 2 years after randomization and then every 6 months for an additional year or until disease recurrence.
Participants in Arm B who recur with IR-NMIBC after TURBT and observation will be offered treatment with cretostimogene as per the treatment schedule in Arm A.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Pathologically confirmed IR-NMIBC, per American Urologic Association/Society of Urologic Oncology/National Comprehensive Cancer Network guidelines, within 90 days of participant randomization:
All visible disease removed by TURBT within 12 weeks of study randomization
Acceptable baseline organ function
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
364 participants in 2 patient groups
Loading...
Central trial contact
Andy Darilek, MD; Shelly Basye, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal